Angsana Molecular: personalizing cancer treatments for Parkway Pantai patients
Parkway Pantai, one of Asia’s largest private healthcare providers, has brought precision medicine into its integrated suite of healthcare services.
Parent company to Singapore’s Mount Elizabeth Hospital, Mount Elizabeth Novena Hospital, Gleneagles Hospital and Parkway East Hospital, Parkway Pantai operates 28 hospitals across Asia and is a leader in its home markets of Singapore, Malaysia and India, as well as growth markets of Hong Kong and China.
Through the acquisition of Angsana Molecular & Diagnostics, Parkway Pantai now has molecular capabilities to customize cancer treatment for each individual patient, allowing doctors and patients to make better informed decisions on how to manage diseases efficiently and safely.
Angsana is the first private College of American Pathologists (CAP) laboratory in Singapore to offer in-house genomic testing for patients with cancer. Its ability to translate genomic technologies into clinical tests puts it at the forefront of genomic medicine. Now a subsidiary of Parkway Pantai, Angsana is expanding the outreach of its portfolio of in-house and partnered tests by its two CAP-accredited laboratories in Singapore and Hong Kong.
The company’s strong track record in partnered tests dates back to its inception in 2016, when it collaborated with US cancer therapy company Ignyta to trial its investigational drug entrectinib, which targets tumors that harbor NTRK1, NTRK2, NTRK3, ROS1 and ALK gene fusions.
Angsana brings the latest, most insightful tests to patients, through either in-house development or distribution on behalf of overseas partners.
Most recently, Angsana became the exclusive distributor in Singapore, Malaysia, Brunei, Myanmar and Vietnam of Agendia’s MammaPrint and Blueprint, well-established tests in the US and Europe with large market potential in Southeast Asia. The 70-gene breast cancer risk-of-recurrence assay shows whether a patient has a low or high risk of cancer recurrence. This helps the physician to personalize treatment management decisions by identifying women who are at a low risk and are therefore unlikely to receive a significant benefit from chemotherapy. MammaPrint and Blueprint are now available to public and private hospitals in these countries.
At the same time, Angsana is focused on developing in-house assays to accompany its existing cancer theranostics tests.
The company’s singular commitment is to translate novel science into high-performance and affordable molecular diagnostic services that make a difference to the lives of patients.
Daniel Tan, CEO
Angsana Molecular & Diagnostics Laboratory Pte Ltd
Tel: +65 6873 9959